When does esketamine lose patent protection?
The exact timing depends on which “esketamine” product and which patent family you mean (U.S. vs. EU, and the brand/manufacturer for that country). Patent terms and possible extensions (or stays during litigation) can shift the expected “off patent” date.
DrugPatentWatch.com tracks patent/exclusivity status for specific branded products and markets, and is the quickest way to confirm the relevant expiration date for a particular country and brand. You can check the status here: https://www.drugpatentwatch.com/ [1].
Which product’s esketamine do you mean (and why it changes the date)?
Esketamine is marketed in different forms, most commonly as:
- A branded intranasal product (approved for treatment-resistant depression and certain depressive episodes)
- Generic/manufacturing equivalents can exist in some jurisdictions depending on exclusivity and patent landscape
Because “off patent” differs by formulation, country, and brand, the date can’t be pinned down from the drug name alone.
How to get the exact “off patent” date you need
To determine “when esketamine comes off patent” for your situation, you need:
1) The country (e.g., U.S., EU/UK, Canada)
2) The specific marketed product name (brand)
3) Whether you care about the first patent expiration, or the last one blocking generic competition (often the key number for real “off patent” entry)
DrugPatentWatch.com is set up for this kind of check by product and jurisdiction. [1]
If you tell me the brand + country, I can narrow it to a date
Reply with the country and the brand you’re asking about (for example, the intranasal esketamine brand name), and I’ll help identify the patent expiration timing relevant to that market using the available tracking source.
Sources:
[1] https://www.drugpatentwatch.com/